secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-134854
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA
-----------------------------------------------------------------------------

- Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).
- 85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); no intraocular inflammation.
- DAYBREAK Phase 3 wet AMD study fully enrolled (690 subjects); topline expected Sept 2026.
- Q4 2025 net loss $56.7M ($1.04/shr); cash $209.9M; Dec 2025 equity raise net $173M.
- KSI-101 Phase 3 PEAK topline 4Q2026, PINNACLE 2Q2027; Phase 1b APEX data showed robust responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/0001193125-26-134854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/kod-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-134854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer